4.7 Article

Renal deposits of complement factors as predictors of end-stage renal disease and death in patients with lupus nephritis

Journal

RHEUMATOLOGY
Volume 59, Issue 12, Pages 3751-3758

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/keaa174

Keywords

biomarker; biopsy; histopathology; immunology; prognosis; systemic lupus erythematosus

Categories

Funding

  1. Niels Stensen Fellowship
  2. Dutch National Association for Lupus, Antiphospholipid Syndrome, Scleroderma and Mixed Connective Tissue Disease
  3. National Institutes of Health [R01 AR057327, K24 AR066109]

Ask authors/readers for more resources

Objective. Lupus nephritis (LN) increases the risks of end-stage renal disease (ESRD) and death, but these risks are difficult to estimate. Since complement factors play an essential role in the pathogenesis and are deposited in the kidneys as C1q and C3, we studied whether these deposits predict ESRD and death in patients with LN. Methods. We collected demographic, clinical and pathological data from 183 adult patients with LN classes II-V diagnosed with a first native kidney biopsy. Pathological data included the localization and intensity of immuno-fluorescence staining of C1q and C3. We obtained dates of incident ESRD and death from the United States Renal Data System and National Death Index, respectively, and evaluated survival curves and hazard ratios for ESRD and death as a composite outcome and as separate outcomes. Results. The presence and intensity of deposits of C1q and C3 in glomeruli, tubular walls and vascular walls differed between classes and were associated with known unfavourable prognostic factors, such as hypertension, hypoalbuminemia and hypocomplementemia. However, over a median follow-up of 7.5 years, their presence and intensity were associated with neither survival free of ESRD and death nor hazard ratios for ESRD and death. Conclusion. Renal deposits of complement factors did not predict ESRD and death in patients with LN.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Rheumatology

Initial disease severity, cardiovascular events and all-cause mortality among patients with systemic lupus erythematosus

Daniel Li, Kazuki Yoshida, Candace H. Feldman, Cameron Speyer, Medha Barbhaiya, Hongshu Guan, Daniel H. Solomon, Brendan M. Everett, Karen H. Costenbader

RHEUMATOLOGY (2020)

Article Rheumatology

Comparison of an administrative algorithm for SLE disease severity to clinical SLE Disease Activity Index scores

Cameron B. Speyer, Daniel Li, Hongshu Guan, Kazuki Yoshida, Emma Stevens, April M. Jorge, Brendan M. Everett, Candace H. Feldman, Karen H. Costenbader

RHEUMATOLOGY INTERNATIONAL (2020)

Article Rheumatology

Development of a Set of Lupus-Specific, Ambulatory Care-Sensitive, Potentially Preventable Adverse Conditions: A Delphi Consensus Study

Candace H. Feldman, Cameron Speyer, Rachel Ashby, Bonnie L. Bermas, Shamik Bhattacharyya, Eliza Chakravarty, Brendan Everett, Elizabeth Ferucci, Aimee O. Hersh, Francisco M. Marty, Joseph F. Merola, Rosalind Ramsey-Goldman, Brad H. Rovin, Mary Beth Son, Laura Tarter, Sushrut Waikar, Jinoos Yazdany, Joel S. Weissman, Karen H. Costenbader

Summary: The study aimed to define a set of SLE-specific adverse outcomes that could be prevented with timely, effective ambulatory care. Through a modified Delphi process, 25 SLE-specific conditions were identified as potentially preventable and important on a population level, falling into categories of vaccine-preventable illnesses, medication-related complications, reproductive health-related complications, and SLE-related complications.

ARTHRITIS CARE & RESEARCH (2021)

Editorial Material Medicine, General & Internal

A Rapid Change in Pressure

Caren G. Solomon

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Article Rheumatology

Elevated Anti-Citrullinated Protein Antibodies Prior to Rheumatoid Arthritis Diagnosis and Risks for Chronic Obstructive Pulmonary Disease or Asthma

Alessandra Zaccardelli, Xinyi Liu, Julia A. Ford, Jing Cui, Bing Lu, Su H. Chu, Peter H. Schur, Cameron B. Speyer, Karen H. Costenbader, William H. Robinson, Jeremy Sokolove, Elizabeth W. Karlson, Carlos A. Camargo, Jeffrey A. Sparks

Summary: Elevated anti-citrullinated protein antibodies (ACPA) before diagnosis of rheumatoid arthritis (RA) in women were associated with increased risk of chronic obstructive pulmonary disease (COPD), while women who later developed RA were more likely to develop asthma compared to non-RA controls.

ARTHRITIS CARE & RESEARCH (2021)

Article Rheumatology

Circulating plasma metabolites and risk of rheumatoid arthritis in the Nurses' Health Study

Su H. Chu, Jing Cui, Jeffrey A. Sparks, Bing Lu, Sara K. Tedeschi, Cameron B. Speyer, LauraKay Moss, Marie L. Feser, Lindsay B. Kelmenson, Elizabeth A. Mewshaw, Jess D. Edison, Kevin D. Deane, Clary Clish, Jessica Lasky-Su, Elizabeth W. Karlson, Karen H. Costenbader

RHEUMATOLOGY (2020)

Article Rheumatology

Using electronic visits (E-visits) to achieve goal serum urate levels in patients with gout in a rheumatology practice: A pilot study

Chio Yokose, April Jorge, Kristin D'Silva, Naomi Serling-Boyd, Mark Matza, Mazen Nasrallah, Sarah Keller, Amar Oza, Hyon Choi, Marcy B. Bolster, Deborah Collier

SEMINARS IN ARTHRITIS AND RHEUMATISM (2020)

Article Rheumatology

Hypouricemia and Mortality Risk in the US General Population

Kristin M. D'Silva, Chio Yokose, Na Lu, Natalie McCormick, Hwajeong Lee, Yuqing Zhang, Hyon K. Choi

Summary: The study found no long-term excess mortality risk among American women with SU levels as low as <3 mg/dl, but observed a 28% higher mortality risk in men with SU levels <4 mg/dl. This suggests a potential causal relationship between hypouricemia and mortality in men, particularly from diabetes mellitus.

ARTHRITIS CARE & RESEARCH (2021)

Article Rheumatology

COVID-19 Outcomes in Patients With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A US Multicenter, Comparative Cohort Study

Kristin M. D'Silva, April Jorge, Andrew Cohen, Natalie McCormick, Yuqing Zhang, Zachary S. Wallace, Hyon K. Choi

Summary: The study found that COVID-19 patients with systemic autoimmune rheumatic diseases may have a higher risk of hospitalization, ICU admission, acute renal failure, and venous thromboembolism compared to those without systemic ARDs. These risks may be largely influenced by comorbidities, except for the risk of venous thromboembolism.

ARTHRITIS & RHEUMATOLOGY (2021)

Article Oncology

Outcomes of Patients With Interstitial Lung Disease Receiving Programmed Cell Death 1 Inhibitors: A Retrospective Case Series

Ioana A. Dobre, Angela J. Frank, Kristin M. D'Silva, David C. Christiani, Daniel Okin, Amita Sharma, Sydney B. Montesi

Summary: This study found that patients with ILD receiving PD-1 inhibitors more frequently died from cancer-related causes than from ILD. Further research is needed to determine the safety of ICIs in patients with ILD and if ILD subtype may help to refine ICI-associated risks.

CLINICAL LUNG CANCER (2021)

Article Rheumatology

COVID-19 and Disease-Modifying Anti-rheumatic Drugs

Kristin M. D'Silva, Zachary S. Wallace

Summary: Baseline glucocorticoid use is associated with severe COVID-19 outcomes in autoimmune disease patients, but DMARDs categories do not appear to increase risk. Randomized clinical trials show glucocorticoids reduce mortality in severe COVID-19, while other agents like baricitinib may improve outcomes in certain populations. More research is needed to guide DMARD management in autoimmune disease patients during the pandemic and their role in COVID-19 treatment.

CURRENT RHEUMATOLOGY REPORTS (2021)

Article Health Care Sciences & Services

Secular Trends in the Pharmacologic Treatment of Osteoporosis and Malignancy-Related Bone Disease from 2009 to 2020

Sara Jane Cromer, Kristin M. D'Silva, Elaine W. Yu, Joan Landon, Rishi J. Desai, Seoyoung C. Kim

Summary: The study found that the use of denosumab has surpassed all other bone-directed therapies over the past decade, especially since its approval in 2010. The use of denosumab also showed increasing trends among patients with osteoporosis, malignancies, and recent fractures. However, it is noteworthy that the proportion of using any bone-directed therapy after fractures is low and has declined over time.

JOURNAL OF GENERAL INTERNAL MEDICINE (2022)

Article Rheumatology

Rituximab for interstitial pneumonia with autoimmune features at two medical centres

Kristin M. D'Silva, Iazsmin Bauer Ventura, Marcy B. Bolster, Flavia Castelino, Amita Sharma, Brent P. Little, Ayodeji Adegunsoye, Mary E. Strek, Hyon Choi, Sydney B. Montesi

Summary: A multicentre observational study examined the use of rituximab (RTX) in interstitial pneumonia with autoimmune features (IPAF) patients. The majority of IPAF patients treated with RTX at two medical centres demonstrated improvement or stability at 1 year, calling for prospective studies to determine the risks, benefits and cost effectiveness of RTX in IPAF.

RHEUMATOLOGY ADVANCES IN PRACTICE (2021)

No Data Available